Table 4 Most common adverse events during neoadjuvant therapy (any grade in ≥10% of patients) irrespective of relationship to treatment
No. of patients with adverse event (%) | NACT alone (n = 30) | NACT + pembrolizumab (n = 61) | ||
|---|---|---|---|---|
Any grade | Grade ≥3 | Any grade | Grade ≥3 | |
Any | 29 (97) | 14 (47) | 61 (100) | 22 (36) |
Asthenia | 13 (43) | 0 | 35 (57) | 2 (3) |
Nausea | 9 (30) | 0 | 26 (43) | 0 |
Anemia | 11 (37) | 2 (7) | 20 (33) | 3 (5) |
Alopecia | 8 (27) | 1 (3) | 18 (30) | 1 (2) |
Abdominal pain | 6 (20) | 1 (3) | 16 (26) | 1 (2) |
Constipation | 5 (17) | 0 | 15 (25) | 0 |
Peripheral neuropathy | 7 (23) | 2 (7) | 14 (23) | 0 |
Arthralgia | 6 (20) | 0 | 13 (21) | 0 |
Neutropenia | 4 (13) | 4 (13) | 13 (21) | 8 (13) |
Diarrhea | 5 (17) | 0 | 10 (16) | 0 |
Rash | 1 (3) | 0 | 10 (16) | 0 |
Thrombocytopenia | 5 (17) | 0 | 7 (11) | 2 (3) |
Hypertension | 1 (3) | 0 | 6 (10) | 2 (3) |
Decreased appetite | 2 (7) | 0 | 6 (10) | 1 (2) |
Myalgia | 0 | 0 | 6 (10) | 0 |
Leukopenia | 5 (17) | 0 | 3 (5) | 1 (2) |
Fatigue | 3 (10) | 0 | 3 (5) | 0 |
